Neurizon Therapeutics Limited has released a press release.
HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Earlier from Neurizon Therapeutics
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study